Grants and Giving
Alnylam Pharmaceuticals funds educational initiatives to advance clinical decision-making in cardiac transthyretin-mediated amyloidosis (ATTR-CM) through practical, evidence-based programs for healthcare professionals.
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (Submission deadline for RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple proposals may be awarded; actual award may be less than requested.
Summary: Supports independent educational initiatives to advance clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM), focusing on practical, real-world impact for healthcare professionals.
Key Information: Only organizations (not individuals) may apply; proposals must be submitted via the Alnylam grant portal.
Description
Alnylam Pharmaceuticals is soliciting proposals for independent educational initiatives that address persistent gaps in the screening, diagnosis, monitoring, and management of transthyretin-mediated amyloidosis (ATTR), specifically cardiac amyloidosis (ATTR-CM). The goal is to equip clinicians with actionable knowledge, tools, and frameworks for practical application in routine care, ultimately improving patient outcomes. This opportunity is open to eligible organizations capable of delivering accredited or non-accredited continuing medical education (CME) activities, with a focus on real-world clinical decision-making.
